Effect of Anluo Huaxian pill combined with entecavir on hepatic fibrosis in patients with non-alcoholic fatty liver disease complicated with chronic hepatitis B
10.3760/cma.j.cn115455-20230524-00544
- VernacularTitle:安络化纤丸联合恩替卡韦对非酒精性脂肪性肝病伴慢性乙型肝炎患者肝纤维化的影响研究
- Author:
Yan WANG
1
;
Lianfeng ZHAO
;
Jian WANG
Author Information
1. 滨州市中心医院感染性疾病科，滨州 251700
- Keywords:
Non-alcoholic fatty liver disease;
Hepatitis B, chronic;
Liver fibrosis;
Anluo Huaxian pill;
Entecavir
- From:
Chinese Journal of Postgraduates of Medicine
2024;47(12):1126-1130
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the effect of Anluo Huaxian pill combined with entecavir on hepatic fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) complicated with chronic hepatitis B (CHB).Methods:A total of 94 patients with NAFLD combined with CHB diagnosed and treated in Binzhou Central Hospital from May 2020 to May 2022 were retrospectively selected and divided into experimental group (47 cases) and control group (47 cases) according to different treatment methods. Patients in both groups received entecavir treatment, and the experimental group received entecavir treatment combined with Anluo Huaxian pill. The clinical treatment effect, the change of traditional Chinese medicine (TCM) symptoms score, liver fibrosis index levels and liver function index levels were compared between the two groups.Results:After treatment, the total clinical effective rate in the experimental group was higher than that in the control group: 91.49%(43/47) vs. 72.34%(34/47), there was statistical difference ( χ2 = 5.82, P<0.05). After treatment, the total scores of the main disease, the total scores of the secondary disease and the total scores of TCM symptoms in the experimental group were lower than those in the control group: (5.26 ± 1.02) scores vs. (6.05 ± 1.21) scores, (3.12 ± 0.59) scores vs. (3.58 ± 0.65) scores, (8.38 ± 1.61) scores vs. (9.63 ± 1.86) scores, there were statistical differences ( P<0.05). After treatment, the levels of glutamyl transpeptidase, alanine aminotransferase, total bilirubin and aspartate aminotransferase, type Ⅳ collagen, type Ⅲ procollagen, hyaluronic acid and laminin in the experimental group were lower than those in the control group: (35.24 ± 1.95) U/L vs. (38.47 ± 2.21) U/L, (23.18 ± 3.24) U/L vs. (25.56 ± 3.58) U/L, (14.25 ± 1.87) μmol/L vs. (15.48 ± 2.06) μmol/L, (30.43 ± 1.78) U/L vs. (34.51 ± 2.14)U/L, (115.27 ± 11.85) μg/L vs. (126.58 ± 12.34) μg/L, (98.75 ± 10.42) μg/L vs. (117.25 ± 11.81) μg/L, (87.51 ± 7.63) μg/L vs. (93.05 ± 8.54) μg/L, (114.65 ± 9.86) μg/L vs. (127.49 ± 10.74) μg/L, there were statistical differences ( P<0.05). Conclusions:Anluo Huaxian pill combined with entecavir in the treatment of NAFLD complicated with CHB has obvious therapeutic effect, which can effectively improve the TCM symptoms score, liver function index levels and prevent liver fibrosis.
